IN8bio, Inc. (NASDAQ:INAB) Short Interest Down 33.6% in May

by · The Markets Daily

IN8bio, Inc. (NASDAQ:INAB – Get Free Report) was the recipient of a significant decrease in short interest during the month of May. As of May 29th, there was short interest totaling 107,416 shares, a decrease of 33.6% from the May 14th total of 161,813 shares. Based on an average daily trading volume, of 82,583 shares, the days-to-cover ratio is currently 1.3 days. Currently, 1.3% of the company’s stock are short sold.

Institutional Investors Weigh In On IN8bio

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. HRT Financial LP purchased a new position in shares of IN8bio during the 4th quarter worth $34,000. Captrust Financial Advisors purchased a new position in shares of IN8bio during the 4th quarter worth $43,000. Texas Capital Bank Wealth Management Services Inc purchased a new position in shares of IN8bio during the 4th quarter worth $56,000. Citadel Advisors LLC purchased a new position in shares of IN8bio during the 3rd quarter worth $54,000. Finally, Two Sigma Investments LP purchased a new position in shares of IN8bio during the 3rd quarter worth $107,000. Hedge funds and other institutional investors own 92.05% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the stock. HC Wainwright restated a “buy” rating on shares of IN8bio in a report on Thursday, June 4th. Weiss Ratings restated a “sell (e+)” rating on shares of IN8bio in a report on Tuesday, April 21st. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $4.00.

View Our Latest Report on IN8bio

IN8bio Trading Down 2.8%

Shares of INAB stock opened at $1.39 on Tuesday. IN8bio has a 12-month low of $1.17 and a 12-month high of $2.73. The firm’s 50 day moving average is $1.53 and its 200 day moving average is $1.77. The stock has a market capitalization of $13.69 million, a P/E ratio of -0.53 and a beta of 0.19.

IN8bio (NASDAQ:INAB – Get Free Report) last issued its earnings results on Thursday, May 7th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.59) by $0.33. As a group, equities analysts predict that IN8bio will post -1.53 earnings per share for the current year.

IN8bio Company Profile

(Get Free Report)

IN8bio is a clinical-stage biopharmaceutical company developing γδ T cell therapeutic and γδ T cell engager (TCE) product candidates to address unmet medical needs. γδ T cells are
a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The Company’s lead programs consist of INB-100, an allogeneic γδ T cell candidate for adult patients with high-risk
leukemias undergoing haploidentical stem cell transplantation.

Further Reading